Core Insights - The forum focused on innovative vaccine development, particularly addressing the challenges and advancements in the field, with a strong emphasis on collaboration between academia and industry [1] Group 1: Vaccine Development Focus - The forum highlighted the urgent need for vaccines against "superbugs," specifically targeting Klebsiella pneumoniae, which has a mortality rate of 40%-50% and causes approximately 800,000 deaths globally each year [2] - The research team from the Army Medical University has identified effective protective components from 6,000 candidate molecules, achieving over 80% protection in pneumonia models against clinical strains of Klebsiella pneumoniae [2] - The collaboration between the Army Medical University and Kangtai Biotech aims to develop the first international vaccine for Klebsiella pneumoniae using reverse vaccinology techniques [2] Group 2: Hepatitis B Vaccine Innovations - The forum discussed the new applications of hepatitis B vaccines in chronic hepatitis B treatment, emphasizing their role in improving anti-HBs seroconversion rates and reducing HBsAg relapse rates [3] - Kangtai Biotech is developing a vaccine aimed at preventing relapse in hepatitis B patients, marking a significant shift from traditional vaccine applications focused solely on healthy populations [3] - If successful, Kangtai Biotech could become the first company in China to offer a comprehensive hepatitis B solution covering prevention, treatment, and relapse prevention [3] Group 3: Multivalent Vaccine Advancements - The forum underscored the importance of multivalent vaccines as a core development direction in preventive vaccines [4] - Kangtai Biotech has developed China's first domestic quadrivalent vaccine and the world's first dual-vector 13-valent pneumococcal conjugate vaccine, both of which have been included in the Chinese Pharmacopoeia [4] - The dual-vector 13-valent vaccine has been registered in countries like Indonesia and Nicaragua, playing a key role in Kangtai Biotech's internationalization strategy [4]